Vaccines may cause wide-scale changes in the immune system which can boost the body’s protection.
Category Archives: Longevity
Be a Voter

Which is better? To encourage someone to vote or to encourage them to be a voter?
If you want the person to actually vote, encourage them to be a voter. It’s been found that this framing is more likely to lead to action.
If you’d like to strengthen a behavior, weave it into your identity. And if you’d like to change someone else’s behavior, encourage them towards an identity change that includes that behavior.
Use this framing with yourself too.
Don’t just get up early. Be an early riser.
Don’t just make a difference. Be a contributor.
Don’t just do personal growth experiments. Be an explorer.
Don’t just post on social media. Be a blogger, podcaster, or YouTuber.
A similar framing shift motivated me to register to vote this year (my first time voting in any political election). Being encouraged to vote never motivated me to change, perhaps because it seemed like a pointless behavior. I decided to vote this time because I want to be a participant, not a spectator. Being a nonvoter in this election doesn’t feel like a good identity to embrace. This time I feel like I have to vote against stupidity in a way that didn’t seem necessary before.
I’ve found this framing especially helpful for leaning into long-term changes, like thinking of myself as an entrepreneur when starting my first business back in 1994. Being an entrepreneur is a stronger frame than starting or running a business. A behavioral frame lets you get a job when you hit a rough patch in your business, but an identity frame makes that option harder to consider.
Consequently, you may want to use behavioral framing when you’d prefer to keep your options open and give yourself more room to pivot. Behavioral framing is more flexible. If, however, you want to feel more committed and focused, so you can really invest in a particular path, identity framing is often the better choice.
Planting parasites: Unveiling common molecular mechanisms of parasitism and grafting

Using the model Orobanchaceae parasitic plant Phtheirospermum japonicum, scientists from Nagoya University and other research institutes from Japan have discerned the molecular mechanisms underlying plant parasitism and cross-species grafting, pinpointing enzyme β-1,4-glucanase (GH9B3) as an important contributor to both phenomena. Targeting this enzyme may help control plant parasitism in crops. Also, this mechanism can be exploited for novel cross-species grafting techniques to realize the goal of sustainable agricultural technologies.
Plant parasitism is a phenomenon by which the parasite plant latches onto and absorbs water and nutrients from a second host plant, with the help of a specialized organ called the “haustorium.” Once the haustorium forms, specific enzymes then help in forming a connection between the tissues of the parasite and host plants, known as a “xylem bridge,” which facilitates the transport of water and nutrients from the host to the parasite.
A similar mechanism is involved in the process of artificial stem grafting, during which, the cell walls of the two different plant tissues at the graft junction become thinner and compressed, a phenomenon made possible by specific cell wall modifying enzymes. Cell wall modification has also been implicated to play a role in parasitism in different lineages of parasitic plants.
Therefore, the research team, led by Dr Ken-ichi Kurotani of Nagoya University, hypothesized that similar genes and enzymes should be involved in the process of parasitism and cross-species grafting. “To investigate molecular events involved in cell-cell adhesion between P. japonicum and the host plant, we analyzed the transcriptome for P. japonicum-Arabidopsis parasitism and P. japonicum-Arabidopsis grafting,” reports Dr Kurotani. When a gene in a cell is activated, it produces an RNA “transcript” that is then translated into an active protein, which is then used by the cell to perform various activities. A “transcriptome” is the complete set of RNA transcripts that the genome of an organism produces under various diverse conditions. The findings of their experiments are published in Nature’s Communications Biology.
Comparison of the parasitism and graft transcriptomes revealed that genes associated with wound healing, cell division, DNA replication, and RNA synthesis were highly upregulated during both events, indicating active cell proliferation at both the haustorium and graft interface.
“What’s more, we found an overlap between the transcriptome data from this study and that from grafting between Nicotiana and Arabidopsis, another angiosperm,” reports Dr Michitaka Notaguchi, the co-corresponding author of the study. Glycosyl hydrolases are enzymes that specifically target the breakdown of cellulose, the primary component of plant cell walls. A β-1,4-glucanase identified in P. japonicum belongs to the glycosyl hydrolase 9B3 (GH9B3) family; an enzyme from the same family was recognized to be crucial for cell-cell adhesion in Nicotiana by Dr Notaguchi’s group.
Further experiments showed that GH9B3-silenced P. japonicum could form the haustorium with Arabidopsis but could not form a functional xylem bridge, meaning that the P. japonicum β-1,4-glucanase is integral for the plant’s parasitic activity. Further, high GH9B3 RNA transcript levels were observed during artificial grafting experiments, thereby proving that the enzyme plays an integral role in both parasitism and grafting mechanisms.
The transcriptome data generated in this study can be used to unearth additional genes and enzymes involved in plant parasitism. Additionally, further research along these directions will help scientists develop specific molecular approaches to arrive at sustainable cross-species grafting alternatives.
Story Source:
Materials provided by Nagoya University. Note: Content may be edited for style and length.
Humidifier care 101

Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Advertising & Sponsorship
Mayo Clinic Marketplace
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Covid: What is the mental health cost to the young?
Could the long-term mental health impact of virus restrictions be far more damaging than the virus itself?
Raising Your Baseline

In practicing the slow, shallow breathing approach from The Oxygen Advantage that I shared about during the past two days, I’m grasping that the key to this approach is to define a new baseline for my breathing and then keep synching back to that new baseline whenever I catch myself drifting from it.
The initial temptation is to sync back to my old way of breathing, which can happen automatically when I lose awareness of my breath. Then I might catch myself and practice consciously reducing my breath so I’m not over-breathing.
An aspect of this change that’s easier to catch is when I moderately exert myself for a short burst, like walking up a flight of stairs. My breathing becomes a little heavier afterwards, so I make a conscious effort to bring it back down quickly, ideally within no more than 2-3 breaths.
So it’s like I have a breathing budget, and I’m doing my best not to squander it. My budget for air this week is much lower than it was last week. And next week I’ll try to nudge it even lower.
I realized that a similar strategy also works for adjusting our emotional baselines.
Suppose you often feel depressed, frustrated, angry, anxious, or some other emotion you’d prefer not to feel so much. Pretend that you’ve suddenly been allocated a lower budget for feeling negative emotions, and you have to be careful not to squander it too quickly.
Imagine if life dramatically cut your negative emotion budget by saying: Henceforth you’re only allowed to spend half as much time in negative emotion territory.
How would you obey this mandate?
You need two pieces to succeed here:
- Frequent check-ins with yourself to see how you’re doing
- A quick recovery strategy to shift from the old behavior to the new one
Whenever you catch yourself experiencing some negative emotion, you must leave that territory and return to a positive or neutral baseline as quickly as possible. Otherwise you’ll squander your negative emotion budget too quickly.
Do you already have such a strategy? Do you know how to quickly shift yourself back to neutral or positive emotional territory? Can you do this within a few breaths?
If you don’t have such a method, then finding one ought to be a key strategic piece for raising your baseline. Being aware of negative emotions isn’t enough – you’ve also got to change them.
To practice reducing my breathing immediately when it’s too rapid, I do the opposite of the unwanted behavior. I deliberately slow down. I can’t breathe slowly and quickly at the same time, so by doing what’s incompatible with rapid breathing, I stop the rapid breathing.
It’s much the same with negative emotion. What’s incompatible with negative emotion? Positive emotion. So if you do something – anything – that makes you feel good within seconds, the negative emotion has to drop off. It can’t hang around while you’re feeling good.
Then the long-term challenge is to habitualize this recovery pattern by always practicing it at every possible opportunity.
I’m doing my best to not let myself over-breathe. Whenever I notice that I’m doing that, I immediately take conscious control of my breathing and slow it down. If I don’t do this, my baseline won’t shift, and I won’t really get to test and experience the results on the other side.
Initially you may have to consciously take control a lot – like dozens of times per day – but if you stay as consistent as you can, you’ll raise your baseline, and the new behavior pattern will become your new default.
Where else could you apply this idea? You could use it for productivity habits, eating habits, early rising, and lots of other areas of life. The key is to develop a rapid strategy for shifting your behavior in a way that’s incompatible with your old baseline. Then apply that shifting behavior every time you catch yourself running the old pattern.
To really create an effective change, the old behavioral baseline must become unacceptable for you. In order to progress to a new baseline, you must eventually regard your old baseline as out of bounds and below standard, even if it still feels normal. This is a simple approach I’ve used repeatedly times for doing personal growth experiments and also for making long-term changes. To embrace the new, there must be some willingness to say: The old behavior is dead to me.
New project to build nano-thermometers could revolutionize temperature imaging

Cheaper refrigerators? Stronger hip implants? A better understanding of human disease? All of these could be possible and more, someday, thanks to an ambitious new project underway at the National Institute of Standards and Technology (NIST).
NIST researchers are in the early stages of a massive undertaking to design and build a fleet of tiny ultra-sensitive thermometers. If they succeed, their system will be the first to make real-time measurements of temperature on the microscopic scale in an opaque 3D volume — which could include medical implants, refrigerators, and even the human body.
The project is called Thermal Magnetic Imaging and Control (Thermal MagIC), and the researchers say it could revolutionize temperature measurements in many fields: biology, medicine, chemical synthesis, refrigeration, the automotive industry, plastic production — “pretty much anywhere temperature plays a critical role,” said NIST physicist Cindi Dennis. “And that’s everywhere.”
The NIST team has now finished building its customized laboratory spaces for this unique project and has begun the first major phase of the experiment.
Thermal MagIC will work by using nanometer-sized objects whose magnetic signals change with temperature. The objects would be incorporated into the liquids or solids being studied — the melted plastic that might be used as part of an artificial joint replacement, or the liquid coolant being recirculated through a refrigerator. A remote sensing system would then pick up these magnetic signals, meaning the system being studied would be free from wires or other bulky external objects.
The final product could make temperature measurements that are 10 times more precise than state-of-the-art techniques, acquired in one-tenth the time in a volume 10,000 times smaller. This equates to measurements accurate to within 25 millikelvin (thousandths of a kelvin) in as little as a tenth of a second, in a volume just a hundred micrometers (millionths of a meter) on a side. The measurements would be “traceable” to the International System of Units (SI); in other words, its readings could be accurately related to the fundamental definition of the kelvin, the world’s basic unit of temperature.
The system aims to measure temperatures over the range from 200 to 400 kelvin (K), which is about -99 to 260 degrees Fahrenheit (F). This would cover most potential applications — at least the ones the Thermal MagIC team envisions will be possible within the next 5 years. Dennis and her colleagues see potential for a much larger temperature range, stretching from 4 K-600 K, which would encompass everything from supercooled superconductors to molten lead. But that is not a part of current development plans.
“This is a big enough sea change that we expect that if we can develop it — and we have confidence that we can — other people will take it and really run with it and do things that we currently can’t imagine,” Dennis said.
Potential applications are mostly in research and development, but Dennis said the increase in knowledge would likely trickle down to a variety of products, possibly including 3D printers, refrigerators, and medicines.
What Is It Good For?
Whether it’s the thermostat in your living room or a high-precision standard instrument that scientists use for laboratory measurements, most thermometers used today can only measure relatively big areas — on a macroscopic as opposed to microscopic level. These conventional thermometers are also intrusive, requiring sensors to penetrate the system being measured and to connect to a readout system by bulky wires.
Infrared thermometers, such as the forehead instruments used at many doctors’ offices, are less intrusive. But they still only make macroscopic measurements and cannot see beneath surfaces.
Thermal MagIC should let scientists get around both these limitations, Dennis said.
Engineers could use Thermal MagIC to study, for the first time, how heat transfer occurs within different coolants on the microscale, which could aid their quest to find cheaper, less energy-intensive refrigeration systems.
Doctors could use Thermal MagIC to study diseases, many of which are associated with temperature increases — a hallmark of inflammation — in specific parts of the body.
And manufacturers could use the system to better control 3D printing machines that melt plastic to build custom objects such as medical implants and prostheses. Without the ability to measure temperature on the microscale, 3D printing developers are missing crucial information about what’s going on inside the plastic as it solidifies into an object. More knowledge could improve the strength and quality of 3D-printed materials someday, by giving engineers more control over the 3D printing process.
Giving It OOMMF
The first step in making this new thermometry system is creating nano-sized magnets that will give off strong magnetic signals in response to temperature changes. To keep particle concentrations as low as possible, the magnets will need to be 10 times more sensitive to temperature changes than any objects that currently exist.
To get that kind of signal, Dennis said, researchers will likely need to use multiple magnetic materials in each nano-object. A core of one substance will be surrounded by other materials like the layers of an onion.
The trouble is that there are practically endless combinations of properties that can be tweaked, including the materials’ composition, size, shape, the number and thickness of the layers, or even the number of materials. Going through all of these potential combinations and testing each one for its effect on the object’s temperature sensitivity could take multiple lifetimes to accomplish.
To help them get there in months instead of decades, the team is turning to sophisticated software: the Object Oriented MicroMagnetic Framework (OOMMF), a widely used modeling program developed by NIST researchers Mike Donahue and Don Porter.
The Thermal MagIC team will use this program to create a feedback loop. NIST chemists Thomas Moffat, Angela Hight Walker and Adam Biacchi will synthesize new nano-objects. Then Dennis and her team will characterize the objects’ properties. And finally, Donahue will help them feed that information into OOMMF, which will make predictions about what combinations of materials they should try next.
“We have some very promising results from the magnetic nano-objects side of things, but we’re not quite there yet,” Dennis said.
Each Dog Is a Voxel
So how do they measure the signals given out by tiny concentrations of nano-thermometers inside a 3D object in response to temperature changes? They do it with a machine called a magnetic particle imager (MPI), which surrounds the sample and measures a magnetic signal coming off the nanoparticles.
Effectively, they measure changes to the magnetic signal coming off one small volume of the sample, called a “voxel” — basically a 3D pixel — and then scan through the entire sample one voxel at a time.
But it’s hard to focus a magnetic field, said NIST physicist Solomon Woods. So they achieve their goal in reverse.
Consider a metaphor. Say you have a dog kennel, and you want to measure how loud each individual dog is barking. But you only have one microphone. If multiple dogs are barking at once, your mic will pick up all of that sound, but with only one mic you won’t be able to distinguish one dog’s bark from another’s.
However, if you could quiet each dog somehow — perhaps by occupying its mouth with a bone — except for a single cocker spaniel in the corner, then your mic would still be picking up all the sounds in the room, but the only sound would be from the cocker spaniel.
In theory, you could do this with each dog in sequence — first the cocker spaniel, then the mastiff next to it, then the labradoodle next in line — each time leaving just one dog bone-free.
In this metaphor, each dog is a voxel.
Basically, the researchers max out the ability of all but one small volume of their sample to respond to a magnetic field. (This is the equivalent of stuffing each dog’s mouth with a delicious bone.) Then, measuring the change in magnetic signal from the entire sample effectively lets you measure just that one little section.
MPI systems similar to this exist but are not sensitive enough to measure the kind of tiny magnetic signal that would come from a small change in temperature. The challenge for the NIST team is to boost the signal significantly.
“Our instrumentation is very similar to MPI, but since we have to measure temperature, not just measure the presence of a nano-object, we essentially need to boost our signal-to-noise ratio over MPI by a thousand or 10,000 times,” Woods said.
They plan to boost the signal using state-of-the-art technologies. For example, Woods may use superconducting quantum interference devices (SQUIDs), cryogenic sensors that measure extremely subtle changes in magnetic fields, or atomic magnetometers, which detect how energy levels of atoms are changed by an external magnetic field. Woods is working on which are best to use and how to integrate them into the detection system.
The final part of the project is making sure the measurements are traceable to the SI, a project led by NIST physicist Wes Tew. That will involve measuring the nano-thermometers’ magnetic signals at different temperatures that are simultaneously being measured by standard instruments.
Other key NIST team members include Thinh Bui, Eric Rus, Brianna Bosch Correa, Mark Henn, Eduardo Correa and Klaus Quelhas.
Before finishing their new laboratory space, the researchers were able to complete some important work. In a paper published last month in the International Journal on Magnetic Particle Imaging, the group reported that they had found and tested a “promising” nanoparticle material made of iron and cobalt, with temperature sensitivities that varied in a controllable way depending on how the team prepared the material. Adding an appropriate shell material to encase this nanoparticle “core” would bring the team closer to creating a working temperature-sensitive nanoparticle for Thermal MagIC.
In the past few weeks, the researchers have made further progress testing combinations of materials for the nanoparticles.
“Despite the challenge of working during the pandemic, we have had some successes in our new labs,” Woods said. “These achievements include our first syntheses of multi-layer nanomagnetic systems for thermometry, and ultra-stable magnetic temperature measurements using techniques borrowed from atomic clock research.”
Hydroxychloroquine does not counter SARS-CoV-2 in hamsters, high dose of favipiravir does: study

Virologists from the KU Leuven Rega Institute in Belgium have shown that a treatment with the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters. A high dose of the anti-flu drug favipiravir, by contrast, has an antiviral effect in the hamsters. The team published their findings in the Proceedings of the National Academy of Sciences (PNAS).
Virologists at the KU Leuven Rega Institute have been working on two lines of SARS-CoV-2 research: searching for a vaccine to prevent infection, and testing existing drugs to see which one can reduce the amount of virus in infected people.
To test the efficacy of the vaccine and antivirals preclinically, the researchers use hamsters. The rodents are particularly suitable for SARS-CoV-2 research because the virus replicates itself strongly in hamsters after infection. Moreover, hamsters develop a lung pathology similar to mild COVID-19 in humans. This is not the case with mice, for example.
For this study, the team of Suzanne Kaptein (PhD), Joana Rocha-Pereira (PhD), Professor Leen Delang, and Professor Johan Neyts gave the hamsters either hydroxychloroquine or favipiravir — a broad-spectrum antiviral drug used in Japan to treat influenza — for four to five days. They tested several doses of favipiravir. The hamsters were infected with the SARS-CoV-2 virus in two ways: by inserting a high dose of virus directly into their noses or by putting a healthy hamster in a cage with an infected hamster. Drug treatment was started one hour before the direct infection or one day before the exposure to an infected hamster. Four days after infection or exposure, the researchers measured how much of the virus was present in the hamsters.
Hydroxychloroquine versus favipiravir
Treatment with hydroxychloroquine had no impact: the virus levels did not decrease and the hamsters were still infectious. “Despite the lack of clear evidence in animal models or clinical studies, many COVID-19 patients have already been treated with hydroxychloroquine,” explains Joana Rocha-Pereira. “Based on these results and the results of other teams, we advise against further exploring the use of hydroxychloroquine as a treatment against COVID-19.”
A high dose of favipiravir, however, had a potent effect. A few days after the infection, the virologists detected hardly any infectious virus particles in the hamsters that received this dose and that had been infected intranasally. Moreover, hamsters that were in a cage with an infected hamster and had been given the drug did not develop an obvious infection. Those that had not received the drug all became infected after having shared a cage with an infected hamster.
A low dose of the drug favipiravir did not have this outcome. “Other studies that used a lower dose had similar results,” Professor Delang notes. “The high dose is what makes the difference. That’s important to know, because several clinical trials have already been set up to test favipiravir on humans.”
Cautious optimism
The researchers are cautiously optimistic about favipiravir. “Because we administered the drug shortly before exposing the hamsters to the virus, we could establish that the medicine can also be used prophylactically, so in prevention,” Suzanne Kaptein notes.
“If further research shows that the results are the same in humans, the drug could be used right after someone from a high-risk group has come into contact with an infected person. It may likely also be active during the early stages of the disease.”
General preventive use is probably not an option, however, because it is not known whether long-term use, especially at a high dose, has side effects.
No panacea
Further research will have to determine whether humans can tolerate a high dose of favipiravir. “In the hamsters, we detected hardly any side effects,” says Delang. In the past, the drug has already been prescribed in high doses to Ebola patients, who appear to have tolerated it well.
“Favipiravir is not a panacea,” the researchers warn. This flu drug, nor any other drug, has not been specifically developed against coronaviruses. As a result, the potency of favipiravir is to be considered moderate at best.
The study also highlights the importance of using small animals to test therapies against SARS-CoV-2 in vivo. “Our hamster model is ideally suited to identify which new or existing drugs may be considered for clinical studies,” explains Professor Johan Neyts. “In the early days of the pandemic, such a model was not yet available. At that time, the only option was to explore in patients whether or not a drug such as hydroxychloroquine could help them. However, testing treatments on hamsters provides crucial information that can prevent the loss of valuable time and energy with clinical trials on drugs that don’t work.”
Not all research models are equal
Kaptein, Rocha-Pereira, Delang and Neyts recently contributed to a commentary in Nature Communications in which they give additional context to the contradictory messages that have been circulating about (hydroxy)chloroquine. In the early days of the pandemic, several studies were set up to test these drugs in cell cultures. The results suggested that they could have an antiviral effect. As a result, clinical trials were organised to test the drugs on humans. However, cell cultures are not the best proxy for the human body, and no conclusive effect was found in humans.
In their commentary, the authors describe several recent studies on human organ-on-chip and other complex in vitro models, mice, hamsters, and non-human primates. Each of these studies demonstrates that hydroxychloroquine and chloroquine do not have the efficacy suggested by the studies in cell cultures. Therefore, the authors conclude that these malaria drugs are very unlikely to be effective in humans as a COVID-19 treatment.
More information
The study “Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity” by Suzanne Kaptein, Johan Neyts, Joana Rocha-Pereira, Leen Delang et al. was published in PNAS.
The commentary “Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients” by Funnell et al. was published in Nature Communications (open access).
Immune cell activation in severe COVID-19 resembles lupus

In severe cases of COVID-19, Emory researchers have been observing an exuberant activation of immune cells, resembling acute flares of systemic lupus erythematosus (SLE), an autoimmune disease.
Their findings point towards tests that could separate some COVID-19 patients who need immune-calming therapies from others who may not. They also may begin to explain why some people infected with SARS-CoV-2 produce abundant antibodies against the virus, yet experience poor outcomes.
The results were published online on Oct. 7 in Nature Immunology.
The Emory team’s results converge with recent findings by other investigators, who found that high inflammation in COVID-19 may disrupt the formation of germinal centers, structures in lymph nodes where antibody-producing cells are trained. The Emory group observed that B cell activation is moving ahead along an “extrafollicular” pathway outside germinal centers — looking similar to they had observed in SLE.
B cells represent a library of blueprints for antibodies, which the immune system can tap to fight infection. In severe COVID-19, the immune system is, in effect, pulling library books off the shelves and throwing them into a disorganized heap.
Before the COVID-19 pandemic, co-senior author Ignacio (Iñaki) Sanz, MD and his lab were focused on studying SLE and how the disease perturbs the development of B cells.
Sanz is head of the division of rheumatology in the Department of Medicine, director of the Lowance Center for Human Immunology, and a Georgia Research Alliance Eminent Scholar. Co-senior author Frances Eun-Hyung Lee, MD is associate professor of medicine and director of Emory’s Asthma/Allergy Immunology program.
“We came in pretty unbiased,” Sanz says. “It wasn’t until the third or fourth ICU patient whose cells we analyzed, that we realized that we were seeing patterns highly reminiscent of acute flares in SLE.”
In people with SLE, B cells are abnormally activated and avoid the checks and balances that usually constrain them. That often leads to production of “autoantibodies” that react against cells in the body, causing symptoms such as fatigue, joint pain, skin rashes and kidney problems. Flares are times when the symptoms are worse.
Whether severe COVID-19 leads to autoantibody production with clinical consequences is currently under investigation by the Emory team. Sanz notes that other investigators have observed autoantibodies in the acute phase of the disease, and it will be important to understand whether long-term autoimmune responses may be related to the fatigue, joint pain and other symptoms experienced by some survivors.
“It’s an important question that we need to address through careful long-term follow-up,” he says. “Not all severe infections do this. Sepsis doesn’t look like this.”
In lupus, extrafollicular B cell responses are characteristic of African-American patients with severe disease, he adds. In the new study, the majority of patients with severe infection were African-American. It will be important to understand how underlying conditions and health-related disparities drive the intensity and quality of B cell responses in both autoimmune diseases and COVID-19, Sanz says.
The study compared 10 critically ill COVID-19 patients (4 of whom died) admitted to intensive care units at Emory hospitals to 7 people with COVID-19 who were treated as outpatients and 37 healthy controls.
People in the critically ill group tended to have higher levels of antibody-secreting cells early on their infection. In addition, the B cells and the antibodies they made displayed characteristics suggesting that the cells were being activated in an extrafollicular pathway. In particular, the cells underwent fewer mutations in their antibody genes than seen in a focused immune response, which is typically honed within germinal centers.
The Nature Immunology paper was the result of a collaboration across Emory. The co-first authors are Matthew Woodruff, PhD, an instructor in Sanz’s lab, and Richard Ramonell, MD, a fellow in pulmonary and critical care medicine at Emory University Hospital.
Ramonell notes that the patients studied were treated early during the COVID-19 pandemic. It was before the widespread introduction of the anti-inflammatory corticosteroid dexamethasone, which has been shown to reduce mortality.
The team’s findings could inform the debate about which COVID-19 patients should be given immunomodulatory treatments, such as dexamethasone or anti-IL-6 drugs. Patients with a greater expansion of B cells undergoing extrafollicular activation also had higher levels of inflammatory cytokines, such as IL-6.
Some COVID-19 patients have been given drugs that push back against IL-6, but results have been mixed in clinical trials. Patients with markers of unregulated immune responses may be appropriate candidates for treatment with anti-inflammatory drugs that target the corresponding pathways, Sanz suggests.
The research was supported by the National Institute of Allergy and Infectious Diseases (U19AI110483 — Emory Autoimmunity Center of Excellence, P01AI125180, R37AI049660, R01AI121252, U01AI141993), the National Institute on Aging (R01AG054991) and the National Heart Lung and Blood Institute (T32HL116271).
Researchers 3D print unique micro-scale fluid channels used for medical testing

In a groundbreaking new study, researchers at the University of Minnesota, in collaboration with the U.S. Army Combat Capabilities Development Command Soldier Center, have 3D printed unique fluid channels at the micron scale that could automate production of diagnostics, sensors, and assays used for a variety of medical tests and other applications.
The team is the first to 3D print these structures on a curved surface, providing the initial step for someday printing them directly on the skin for real-time sensing of bodily fluids. The research is published in Science Advances.
Microfluidics is a rapidly growing field involving the control of fluid flows at the micron scale (one millionth of a meter). Microfluidics are used in a wide range of application areas including environmental sensing, medical diagnostics (such as COVID-19 and cancer), pregnancy testing, drug screening and delivery, and other biological assays.
The global microfluidics market value is currently estimated in the billions of dollars. Microfluidic devices are typically fabricated in a controlled-environment cleanroom using a complex, multi-step technique called photolithography. The fabrication process involves a silicone liquid that is flowed over a patterned surface and then cured so that the patterns form channels in the solidified silicone slab.
In this new study, the microfluidic channels are created in a single step using 3D printing. The team used a custom-built 3D printer to directly print the microfluidic channels on a surface in an open lab environment. The channels are about 300 microns in diameter — about three times the size of a human hair (one one-hundredth of an inch). The team showed that the fluid flow through the channels could be controlled, pumped, and re-directed using a series of valves.
Printing these microfluidic channels outside of a cleanroom setting could provide for robotic-based automation and portability in producing these devices. For the first time, the researchers were also able to print microfluidics directly onto a curved surface. In addition, they integrated them with electronic sensors for lab-on-a-chip sensing capabilities.
“This new effort opens up numerous future possibilities for microfluidic devices,” said Michael McAlpine, a University of Minnesota mechanical engineering professor and senior researcher on the study. “Being able to 3D print these devices without a cleanroom means that diagnostic tools could be printed by a doctor right in their office or printed remotely by soldiers in the field.”
But McAlpine said the future is even more compelling.
“Being able to print on a curved surface also opens up many new possibilities and uses for the devices, including printing microfluidics directly on the skin for real-time sensing of bodily fluids and functions,” said McAlpine, who holds the Kuhrmeyer Family Chair Professorship in the Department of Mechanical Engineering.
Story Source:
Materials provided by University of Minnesota. Note: Content may be edited for style and length.
